Elrexfio — elranatamab
Named-patient access overview. Elrexfio is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Elrexfio
Elrexfio (elranatamab) is manufactured by Pfizer and indicated for R/R multiple myeloma. It is a BCMAxCD3 BsAb approved by the US FDA in 2023 and may be accessible to international patients through Named Patient Program or personal-import pathways.
How Reserve Meds coordinates Elrexfio
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Elrexfio for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Elrexfio is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
We have documented named-patient access pathways for Elrexfio in the countries below. Each page outlines the destination-country regulatory posture, typical timeline, and physician-credential requirements.
Elrexfio in BahrainNamed-patient access, timeline, and regulatory notes
Elrexfio in OmanNamed-patient access, timeline, and regulatory notes
Elrexfio in QatarNamed-patient access, timeline, and regulatory notes
Elrexfio in Sri LankaNamed-patient access, timeline, and regulatory notes
Elrexfio in TurkeyNamed-patient access, timeline, and regulatory notes
Elrexfio in United Arab EmiratesNamed-patient access, timeline, and regulatory notes
Start a request for Elrexfio
Submit a 60-second intake. Our clinical team responds within one business day with case-specific feasibility, timeline, and a formal quote.